Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed a Form 8-K dated May 7, 2024, reporting a notification from the New York Stock Exchange regarding noncompliance with its continued listing requirements. This filing does not report quarterly or annual financial results.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material changes versus the prior comparable period
- The NYSE notified the Company that its Class A common stock had an average closing price below $1.00 per share over a consecutive 30-trading-day period.
- The notice does not result in immediate delisting. The Company has six months from receipt of the notice to regain compliance.
- The stock will continue trading on the NYSE under the symbol “DNA,” with an added “.BC” designation indicating noncompliance with NYSE continued listing standards.
Guidance, outlook, risks, contingencies, and unusual items
- The Company intends to notify the NYSE within 10 business days of its intent to regain compliance and is considering all available options.
- Compliance may be restored if, on the last trading day of a calendar month during the cure period, the stock closes at or above $1.00 and has a 30-trading-day average closing price of at least $1.00.
- If the Company does not regain compliance within the cure period, the NYSE will initiate procedures to suspend and delist the Class A common stock.
- Management’s statements regarding regaining compliance are forward-looking and subject to risks, including securities-price volatility, business and regulatory conditions, demand for synthetic biology and biosecurity services, competition, legal proceedings, execution of Foundry platform programs, and customer commercialization outcomes.
- The filing does not state the specific date on which the six-month cure period expires.
Important facts for investors to verify
- Verify the date the Company received the NYSE notice and the resulting deadline for curing the deficiency.
- Monitor the stock’s closing price and 30-trading-day average against the $1.00 requirement.
- Review any subsequent filings describing the Company’s remediation plan or NYSE determination.
- Assess the possibility and potential effects of suspension or delisting if compliance is not restored.
- Review the Company’s latest Form 10-K, Form 10-Q, and risk-factor disclosures for broader financial and operating risks.